Table 1 Demographic and baseline characteristics (safety population)
| Â | Lumiracoxib 400 mg od (n= 154) | Rofecoxib 25 mg od (n= 155) |
|---|---|---|
Age (years)†| 65.3 ± 8.49 | 65.5 ± 8.67 |
Women, n (%) | 94 (61.0) | 100 (64.5) |
BMI (kg/m2)†| 29.1 ± 5.21 | 28.3 ± 4.51 |
Race | Â | Â |
   Caucasians, n (%) | 154 (100.0) | 153 (98.7) |
   Other | 0 (0.0) | 2 (1.2) |
Disease duration (years)†| 7.41 ± 7.058 | 8.37 ± 8.407 |
Physician's global assessment of disease activity n (%) | Â | Â |
   Very good | 1 (0.6) | 2 (1.3) |
   Good | 3 (1.9) | 5 (3.2) |
   Fair | 75 (48.7) | 66 (42.6) |
   Poor | 69 (44.8) | 76 (49.0) |
   Very poor | 6 (3.9) | 6 (3.9) |
Patient's global assessment of disease activity n (%) | Â | Â |
   Very good | 1 (0.6) | 1 (0.6) |
   Good | 9 (5.8) | 6 (3.9) |
   Fair | 51 (33.1) | 57 (36.8) |
   Poor | 78 (50.6) | 77 (49.7) |
   Very poor | 15 (9.7) | 14 (9.0) |
Pain intensity assessment n (%) | Â | Â |
   Moderate | 74 (48.1) | 74 (47.7) |
   Severe | 67 (43.5) | 67 (43.2) |
   Extreme | 13 (8.4) | 14 (9.0) |
Current smokers, n (%) | 24 (15.6) | 26 (16.8) |